Predicate |
Object |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D495-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D495-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4365 |
filingDate |
2011-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationDate |
2013-07-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
JP-2013528221-A |
titleOfInvention |
Crystalline form of kinase inhibitor |
abstract |
N- (4- {4-amino-7- [1- (2-hydroxyethyl) -1H-pyrazol-4-yl] thieno [3,2-c] pyridin-3-yl} phenyl) -N′- (3-Fluorophenyl) urea citrate and its crystalline form are suitable pharmaceutical ingredients for pharmaceutical compositions useful in the treatment of diseases such as cancer. |
priorityDate |
2010-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |